Unibest

Pharmaceutical intermediates

(LCZ696) Intermediates

3 pharmaceutical intermediates for (LCZ696). Indication: Hypertension; Essential hypertension; Heart failure.

提交项目All intermediates

About (LCZ696)

Originator
Novartis Pharmaceuticals Corp
Indication
Hypertension; Essential hypertension; Heart failure
Approved Date
07/07/2015
DS/DP
01/15/2025

Available intermediates

3 intermediates currently listed for (LCZ696). Request specifications, documentation or a quotation for any item below.

(LCZ696) intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
AHU-377 (heMicalciuM salt)1369773-39-6//
(2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpentanoic acid1012341-50-2//
(R,E)-5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpent-2-enoic acid1012341-48-8//

Other programs under L

LanifibranorLapatinibLarotrectinibLasmiditanLazertinib MesylateLemborexantLenacapavir sodiumLenalidomide

Building toward (LCZ696)?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →